Edwards Lifesciences Co. (NYSE:EW) Shares Sold by Larson Financial Group LLC

Larson Financial Group LLC cut its stake in shares of Edwards Lifesciences Co. (NYSE:EW) by 22.2% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 3,415 shares of the medical research company’s stock after selling 976 shares during the period. Larson Financial Group LLC’s holdings in Edwards Lifesciences were worth $253,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of EW. Leavell Investment Management Inc. increased its holdings in Edwards Lifesciences by 3.3% during the 3rd quarter. Leavell Investment Management Inc. now owns 9,923 shares of the medical research company’s stock worth $655,000 after purchasing an additional 321 shares during the last quarter. State of New Jersey Common Pension Fund D increased its holdings in Edwards Lifesciences by 3.1% during the 3rd quarter. State of New Jersey Common Pension Fund D now owns 226,465 shares of the medical research company’s stock worth $14,944,000 after purchasing an additional 6,723 shares during the last quarter. Kennebec Savings Bank purchased a new stake in Edwards Lifesciences during the 3rd quarter worth approximately $79,000. Patten & Patten Inc. TN increased its holdings in Edwards Lifesciences by 7.5% during the 3rd quarter. Patten & Patten Inc. TN now owns 164,904 shares of the medical research company’s stock worth $10,882,000 after purchasing an additional 11,512 shares during the last quarter. Finally, Addison Advisors LLC increased its holdings in Edwards Lifesciences by 915.1% during the 3rd quarter. Addison Advisors LLC now owns 18,038 shares of the medical research company’s stock worth $1,190,000 after purchasing an additional 16,261 shares during the last quarter. 79.46% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, CEO Bernard J. Zovighian sold 6,164 shares of the firm’s stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $69.51, for a total transaction of $428,459.64. Following the completion of the transaction, the chief executive officer now owns 59,083 shares of the company’s stock, valued at $4,106,859.33. This trade represents a 9.45 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, VP Daniel J. Lippis sold 2,500 shares of the firm’s stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $74.08, for a total value of $185,200.00. Following the transaction, the vice president now directly owns 23,189 shares of the company’s stock, valued at $1,717,841.12. This represents a 9.73 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 44,303 shares of company stock worth $3,255,356. 1.29% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on EW shares. Truist Financial restated a “hold” rating and set a $78.00 price objective (up from $70.00) on shares of Edwards Lifesciences in a report on Thursday, December 5th. Citigroup boosted their price target on Edwards Lifesciences from $81.00 to $83.00 and gave the company a “buy” rating in a report on Wednesday, December 11th. Evercore ISI lowered their price target on Edwards Lifesciences from $75.00 to $73.00 and set an “in-line” rating for the company in a report on Wednesday, February 12th. Morgan Stanley boosted their price target on Edwards Lifesciences from $70.00 to $75.00 and gave the company an “equal weight” rating in a report on Wednesday, February 12th. Finally, Wolfe Research downgraded Edwards Lifesciences from a “hold” rating to a “strong sell” rating in a report on Wednesday, February 12th. One research analyst has rated the stock with a sell rating, fourteen have issued a hold rating and twelve have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $79.95.

Edwards Lifesciences Trading Down 2.6 %

Shares of EW stock opened at $68.49 on Tuesday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. Edwards Lifesciences Co. has a 1 year low of $58.93 and a 1 year high of $96.12. The stock has a fifty day moving average of $72.14 and a two-hundred day moving average of $70.37. The firm has a market capitalization of $40.26 billion, a PE ratio of 9.83, a price-to-earnings-growth ratio of 4.82 and a beta of 1.12.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. As a group, research analysts expect that Edwards Lifesciences Co. will post 2.45 EPS for the current year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.